Netarsudil

Rho-kinase inhibitors

Netarsudil is the first representative of an innovative therapeutic class that increases conventional trabecular outflow, acting directly on the physiological site of greatest resistance in glaucoma.

Mechanism

💊 Commercial Names

Rhopressa, Rocklatan (fixed coformulation with Latanoprost).

🔬 Pharmacological Group

Selective inhibitor of the Rho-kinase enzyme (ROCK-1 and ROCK-2). Ocular antihypertensive.

Mechanism of Action

Netarsudil acts by blocking intracellular signaling mediated by the small GTPase Rho and its effector kinase (ROCK):

Selective inhibition of ROCK-1 and ROCK-2: Reversibly blocks the kinase catalytic site of conventional trabecular meshwork cells and Schlemm's canal.
Actomyocin Cytoskeleton Disorganization: By inhibiting the phosphorylation of myosin light chain phosphatase (MLCP), intrinsic cellular contractility and the density of actin stress fibers in trabecular tissue decrease. The mesh cells relax and contract, physically opening the cribriform filtration spaces.
Additional Integrated Hypotensive Mechanisms:
1. Reduction of Episcleral Venous Pressure: By relaxing the cell wall of the episcleral collecting vessels, the remaining IOP is directly reduced.
2. Norepinephrine Transporter (NET) Inhibition: Increases local dural availability of norepinephrine, compensatory stimulation of additional adrenergic receptors and further reducing aqueous humor synthesis.

Pharmacokinetics

Quantitative Ocular and Systemic Pharmacokinetics

Netarsudil is a high local affinity molecule formulated in a water-soluble ophthalmic solution:

Parameter	Quantitative Pharmacokinetic Profile (Netarsudil 0.02%)
Rout of Administration	Ophthalmic topical solution. Dosage: 1 drop per day, preferably at night.
Direct Ocular Metabolism	It is a soft prodrug. After penetrating the cornea, it undergoes enzymatic hydrolysis by ocular esterases to become the active metabolite for prolonged dural retention: AR-13352.
Plasma Bioavailability	Nil or below the limits of analytical quantification in plasma (<0.1 ng/mL) due to localized ocular metabolic degradation and its rapid tissue clearance.
Onset and Duration of Effect	Onset detectable in the first 2 hours; maximum IOP reduction in 8 to 12 hours. Duration of sustained hypotensive effect greater than 24 hours.

Security

Contraindications

Absolute: Known hypersensitivity to netarsudil or any of the excipients of the eye drops.
Relative: Pre-existing Fuchs corneal dystrophy (associated with worsening transparency or bullous keratopathy); severe hepatic or renal failure (although its systemic absorption is negligible, it lacks robust safety studies).

Adverse Effects (ADR)

Local Ocular: Severe conjunctival hyperemia (occurs in up to 50% of treated patients, of direct physiological origin due to local vasodilation of the conjunctival and episcleral vessels due to ROCK inhibition); Cornea Verticillata / Vortex Keratopathy (accumulation of bilateral symmetrical lipid microcrystalline deposits in the cytoplasm of the basal corneal epithelium, with an asymptomatic course and completely reversible after stopping treatment); self-limiting punctate subconjunctival hemorrhages in the inferior fornix.
Systemic: Little or no effects on heart rate, blood pressure or lung dynamics due to local ocular metabolism and no free systemic absorption.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousDorzolamide, Brinzolamide, Acetazolamide NextPilocarpine

System: Ophthalmology
Cluster: Rho-kinase inhibitors

Download Epistemis